Argentina’s government began administering second doses of the Russian Sputnik V coronavirus vaccine Tuesday after receiving another shipment of 300,000 shots at the weekend.
Argentina began its immunization campaign on December 29 with the first 300,000 doses of the vaccine made by Russia’s Gamaleya laboratory.
It is prioritizing health care workers in this first phase.
“The immunization campaign has been developing in a timely fashion,” Health Minister Gines Gonzalez Garcia said.
The country of 44 million has recorded more than 1.8 million cases and almost 46,000 deaths from COVID-19.
Argentina was the first Latin American country, on December 23, to approve the “emergency use” of Sputnik V despite a lack of clinical trials.
The government has an agreement to purchase another 19.4 million doses by the end of February with an option for an extra five million.
Argentina has committed to buying 51 million doses in total and has also signed deals to purchase the AstraZeneca/Oxford and Covax vaccines.
Negotiations are ongoing to procure the vaccine made by US pharmaceutical giant Pfizer with German biotechnology firm BioNTech.
The next stages of the immunization program will see the over 60s and people suffering from at least two illnesses receiving vaccines.
Meanwhile, Chile began immunizing its general population on Monday, starting with those over 80 or suffering from chronic illnesses.
Chile started immunizing health care workers on December 24 and has signed deals to purchase 30 million doses.
It has reported 670,000 cases and 17,500 deaths amongst its 18 million population.
Argentina first in Latin America to approve Russian vaccine
© 2021 AFP
Argentina begins administering second Sputnik V doses (2021, January 19)
retrieved 19 January 2021
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.
- COVID case rates hit new high for England, study finds - April 7, 2022
- Govt’s focus on affordable healthcare ensured significant savings for poor, middle class: PM Modi - April 7, 2022
- SRL Diagnostics and Skye Air Mobility collaborate to transport pathology samples using drone logistics - April 6, 2022
- Healthineers sets up new production line of CT scanners in Bengaluru under PLI scheme - April 6, 2022
- Lupin inks licensing pact with Alvion to market drugs in Southeast Asia - April 6, 2022
- Yoga Mahotsav: Ayush Ministry to organise event to demonstrate common yoga on World Health Day - April 6, 2022
- LordsMed forays into the medtech space with launch of health ATMs ‘Lords Sehat’ - April 5, 2022
- ‘Friendly viruses’ can be the next big thing in the history of medical research and more - April 5, 2022
- No setback to Bharat Biotech even as WHO suspends Covaxin UN supply: Sources - April 4, 2022
- Govt panel recommends Serum’s Covovax dose for kids aged 12 and above - April 4, 2022